Journal of Cardiovascular Electrophysiology | 2019
Amiodarone is associated with adverse outcomes in patients with sustained ventricular arrhythmias upgraded to cardiac resynchronization therapy—defibrillators
Abstract
Amiodarone reduces recurrent ventricular tachyarrhythmias (VTA) but may worsen cardiovascular outcomes in heart failure (HF) patients. Cardiac resynchronization therapy (CRT) may also be antiarrhythmic. When patients with prior sustained VTA are upgraded to CRT defibrillators (CRT‐D) from conventional implantable cardioverter‐defibrillators (ICDs), should concomitant amiodarone be continued or is CRT’s antiarrhythmic potential sufficient?